We are international
• about myeloma TEXT SIZE   

Summer 2005 Volume 6, Issue 5:
IMF Honors Kenneth C. Anderson, MD with 2005 Robert A. Kyle Lifetime Achievement Award
By Robert A. Kyle, MD
Dr. Anderson has done more for the field of multiple myeloma and related disorders than anyone else. He is most deserving of this Lifetime Achievement Award.
Drs. Robert A. Kyle and Kenneth C. Anderson

Kenneth C. Anderson, MD, of the Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, will receive the 2005 Robert A. Kyle Lifetime Achievement Award on September 27th.

Dr. Anderson has developed the world’s most successful research and clinical program devoted to multiple myeloma. He has attracted many talented young investigators and has led them in making important contributions to the understanding of multiple myeloma and ultimately to successful therapy of this devastating disease. His group consists of young research fellows as well as seasoned researchers, molecular biologists, immunologists, transplant biologists, and clinicians who effectively work together. He and his group developed monoclonal antibodies that are used to characterize the B-cell malignancies. These antibodies have been utilized to purge tumor cells from the collected hematopoietic stem cells. They have pointed out that adhesion molecules on myeloma cells play an important role in localizing tumor cells within the bone marrow and also, in regulating tumor cell growth and survival. They have clarified the mechanisms of regulating autocrine and paracrine cell growth at both the cellular and molecular levels. They have developed a model of human myeloma using SCID mice which allows the study of the mechanisms of plasma cell growth in vivo. Dr. Anderson and his colleagues have also demonstrated multiple abnor-malities in the cell cycle regulatory proteins which result in abnormal growth, control, and survival. Signaling cascades mediating cell growth, survival, and drug resistance have also been delineated. They have shown that apoptotic pathways in myeloma cells are important. Furthermore, mechanisms of resistance to apoptosis have been studied in an effort to develop new therapies for myeloma. They have emphasized the role of the microenvironment in regulating growth and survival of myeloma tumor cells. Most importantly, these studies have identified multiple agents targeting the tumor cell-tumor host interaction.

These laboratory investigations have resulted in important new therapies for the treatment of mul-tiple myeloma at the bedside. Dr. Anderson and his group have developed novel immune-based therapeutic approaches for multiple myeloma. These include the development of anti-tumor vaccines as well as ex vivo expansion of allogeneic and autologous antigen specific T cells, for allografting and autografting respectively. His laboratory has identified new treatment targets of the tumor cell and its bone marrow microenvironment. They have designed and lead multiple clinic protocols to demonstrate the efficacy of these agents. Most importantly, Dr. Anderson’s group played a major role in the development of the proteasome inhibitor, bortezomib. His identification and validation of targets to improve patient outcome in myeloma shows great promise.

Born in Worcester, Massachusetts, Kenneth Anderson graduated from Boston University, and received his MD from Johns Hopkins University School of Medicine in Baltimore, Maryland. Following internship and medical residency at Johns Hopkins, he became a fellow in medical oncology at Dana-Farber Cancer Institute. He was also a clinical fellow in medicine at Brigham and Women’s Hospital. He advanced from Instructor in Medicine to Professor of Medicine, and is currently the Kraft Family Professor of Medicine, Harvard Medical School. He is currently Chief, Division of Hematologic Neoplasia, Dana-Farber, and Director of the Jerome Lipper Multiple Multiple Myeloma Center.

Dr. Anderson has received many honors, including the Waldenström Award for Myeloma Research as well as the Doris Duke Clinical Research Clinical Scientist Award. He has served as visiting professor at many prestigious institutions, including Yale University, University of Pennsylvania, and University of Chicago. Dr. Anderson has also given many lectureships including the University of Utah, University of Puerto Rico and Mayo Clinic. He has also served on the editorial boards of BLOOD, Journal of Clinical Oncology, Transfusion, and American Journal of Hematology. Dr. Anderson is Associate Editor of the European Journal of Haematology and Section Editor of Myeloma for Leukemia. His bibliography is impressive from both a qualitative and quantitative standpoint and consists of more than 400 peer-reviewed papers, book chapters, and books.

Dr. Anderson is Chair of the National Comprehensive Cancer Network (NCCN), Multiple Myeloma Clinical Practice Guidelines Committee, and is a Cancer and Leukemia Group B principal investigator. He serves on the Scientific Advisory Board of the International Myeloma Foundation. He is also on the Board of Directors and Chair of the Scientific Advisory Board of the Multiple Myeloma Research Foundation, as well as on the Board of Directors and Chair of the Leadership Committee of the Multiple Myeloma Research Consortium. Dr. Anderson has served on the National Cancer Institute Scientific Review Group D and was cochairman of the National Cancer Institute Progress Review Group on Leukemia, Lymphoma and Myeloma. He also serves on external Advisory Committees at the University of Indiana Cancer Center, MD Anderson Cancer Center, and the Amyloid Center at Boston University.

It is evident from his many activities that Ken is never too busy to help others. Dr. Anderson has done more for the field of multiple myeloma and related disorders than anyone else. He is most deserving of this Lifetime Achievement Award.

 related articles